NASDAQ:KYMR Kymera Therapeutics (KYMR) Stock Price, News & Analysis $117.75 -0.73 (-0.62%) Closing price 09/18/2026 04:00 PM EasternExtended Trading$117.75 0.00 (0.00%) As of 09/18/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Kymera Therapeutics Stock (NASDAQ:KYMR) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Kymera Therapeutics alerts:Sign Up Key Stats Today's Range$116.36▼$119.0650-Day Range$100.31▼$127.3152-Week Range$47.90▼$130.05Volume1.90 million shsAverage Volume599,332 shsMarket Capitalization$9.79 billionP/E RatioN/ADividend YieldN/APrice Target$131.63Consensus RatingModerate Buy Company Overview Kymera Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing medicines that selectively remove disease-causing proteins from cells. The company’s approach is based on targeted protein degradation, which uses small-molecule degraders to direct unwanted proteins to the cell’s natural disposal system rather than simply blocking their activity. Kymera’s research and development activities are supported by its proprietary Pegasus platform, which is designed to identify degradable proteins and create drug candidates against them. The company has focused on immune-mediated and inflammatory diseases, as well as certain cancers, where targeted protein degradation may address biological targets that have been difficult to treat with conventional medicines. Its development programs have included KT-474, also known as SAR444656, an IRAK4 degrader investigated for inflammatory diseases including atopic dermatitis and hidradenitis suppurativa, and KT-621, a STAT6 degrader being developed for immune-mediated conditions. Kymera has also established collaborations with pharmaceutical companies, including Sanofi, to advance selected protein-degradation programs. The company is headquartered in Watertown, Massachusetts, and was co-founded by Nello Mainolfi, Ph.D., who has served as its chief executive officer.AI Generated. May Contain Errors. Read More Kymera Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks33rd Percentile Overall ScoreKYMR MarketRank™: Kymera Therapeutics scored higher than 33% of companies evaluated by MarketBeat, and ranked 721st out of 897 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.4 / 5Analyst RatingModerate Buy Consensus RatingKymera Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.88, and is based on 1 strong buy rating, 21 buy ratings, 2 hold ratings, and 1 sell rating.Upside PotentialKymera Therapeutics has a consensus price target of $131.63, representing about 11.8% upside from its current price of $117.75.Amount of Analyst CoverageKymera Therapeutics has been the subject of 17 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Kymera Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Kymera Therapeutics are expected to decrease in the coming year, from ($3.83) to ($5.08) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Kymera Therapeutics is -36.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Kymera Therapeutics is -36.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioKymera Therapeutics has a P/B Ratio of 6.06. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Kymera Therapeutics' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted14.85% of the float of Kymera Therapeutics has been sold short.Short Interest Ratio / Days to CoverKymera Therapeutics has a short interest ratio ("days to cover") of 16.83, which indicates bearish sentiment.Change versus previous monthShort interest in Kymera Therapeutics has recently decreased by 0.11%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldKymera Therapeutics does not currently pay a dividend.Dividend GrowthKymera Therapeutics does not have a long track record of dividend growth. News and Social Media2.2 / 5News Sentiment0.57 News SentimentKymera Therapeutics has a news sentiment score of 0.57. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Kymera Therapeutics this week, compared to 7 articles on an average week.Search InterestOnly 5 people have searched for KYMR on MarketBeat in the last 30 days. This is a decrease of -38% compared to the previous 30 days.MarketBeat Follows2 people have added Kymera Therapeutics to their MarketBeat watchlist in the last 30 days. Company Ownership1.3 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Kymera Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $365,904,088.00 in company stock.Percentage Held by Insiders15.98% of the stock of Kymera Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsKymera Therapeutics has minimal institutional ownership at this time.Read more about Kymera Therapeutics' insider trading history. Receive KYMR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Kymera Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. KYMR Stock News HeadlinesJ.P. Morgan Sticks to Its Buy Rating for Kymera Therapeutics (KYMR)September 18 at 7:51 AM | theglobeandmail.comKymera Therapeutics, Inc. (KYMR) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptSeptember 15, 2026 | seekingalpha.comMan who Predicted Trump 2016 Win: “Prepare for Mid-Term Meltdown”In 2016, major election models gave Hillary Clinton a 99% chance of winning - but former CIA and Pentagon adviser Jim Rickards publicly predicted a Trump victory before election night. Now Rickards is issuing a new forecast he calls a potential mid-term meltdown, one he believes could send shockwaves through financial markets.September 20 at 1:00 AM | Paradigm Press (Ad)Analysts Offer Insights on Healthcare Companies: Kymera Therapeutics (KYMR) and Intuitive Surgical (ISRG)September 15, 2026 | theglobeandmail.comKymera Therapeutics, Inc. (NASDAQ:KYMR) Receives Consensus Recommendation of "Moderate Buy" from AnalystsSeptember 15, 2026 | americanbankingnews.comBofA Securities Adjusts Kymera Therapeutics Price Target to $144 From $123September 14, 2026 | marketscreener.comMKymera Therapeutics, Inc. (KYMR) Presents at Citigroup's Biopharma Back to School Summit 2026 TranscriptSeptember 11, 2026 | seekingalpha.comBrian Adams Sells 6,371 Shares of Kymera Therapeutics (NASDAQ:KYMR) StockSeptember 5, 2026 | insidertrades.comSee More Headlines KYMR Stock Analysis - Frequently Asked Questions How have KYMR shares performed this year? Kymera Therapeutics' stock was trading at $77.81 on January 1st, 2026. Since then, KYMR shares have increased by 51.3% and is now trading at $117.75. How were Kymera Therapeutics' earnings last quarter? Kymera Therapeutics, Inc. (NASDAQ:KYMR) posted its quarterly earnings data on Wednesday, August, 5th. The company reported ($0.62) EPS for the quarter, topping the consensus estimate of ($0.71) by $0.09. The company's revenue for the quarter was up 465.2% compared to the same quarter last year. Read the conference call transcript. When did Kymera Therapeutics IPO? Kymera Therapeutics (KYMR) raised $148 million in an initial public offering (IPO) on Friday, August 21st 2020. The company issued 8,684,800 shares at a price of $16.00-$18.00 per share. Morgan Stanley, BofA Securities, Cowen and Guggenheim Securities acted as the underwriters for the IPO. Who are Kymera Therapeutics' major shareholders? Top institutional shareholders of Kymera Therapeutics include BlackRock Inc. (6.73%), Wellington Management Group LLP (4.42%), Atlas Venture Life Science Advisors LLC (3.42%) and Merck & Co. Inc. (0.94%). Insiders that own company stock include Bros Advisors Lp Baker, Venture Fund X LP Atlas, Nello Mainolfi, Bruce Booth, Bruce N Jacobs, Bvf Partners L P/Il, Jared Gollob, Ellen Chiniara, Brian Adams, Noah Goodman, Jeremy G Chadwick, Elena Ridloff and Joanna Horobin. View institutional ownership trends. How do I buy shares of Kymera Therapeutics? Shares of KYMR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Kymera Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Kymera Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Netflix (NFLX), Tesla (TSLA), JPMorgan Chase & Co. (JPM) and First Solar (FSLR). Company Calendar Last Earnings8/05/2026Today9/20/2026Stifel 2026 Virtual Immunology and Inflammation Forum9/24/2026Next Earnings (Estimated)11/03/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (16m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 KYMR's financial health is in the Green zone, according to TradeSmith. KYMR has been in this zone for over 16 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:KYMR CIK1815442 Webwww.kymeratx.com Phone(857) 285-5314FaxN/AEmployees273Year Founded2017Price Target and Rating Average Price Target for Kymera Therapeutics$131.63 High Price Target$180.00 Low Price Target$97.00 Potential Upside/Downside+11.8%Consensus RatingModerate Buy Rating Score (0-4)2.88 Research Coverage25 Analysts Profitability EPS (Trailing Twelve Months)($3.24) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$311.35 million Net Margins-285.33% Pretax Margin-285.33% Return on Equity-21.22% Return on Assets-19.21% Debt Debt-to-Equity RatioN/A Current Ratio10.34 Quick Ratio10.34 Sales & Book Value Annual Sales$39.21 million Price / Sales249.70 Cash FlowN/A Price / Cash FlowN/A Book Value$19.42 per share Price / Book6.06Miscellaneous Outstanding Shares83,150,000Free Float69,863,000Market Cap$9.79 billion OptionableOptionable Beta1.96 Social Links The Infrastructure's Backbone: 10 Stocks Powering the AI BuildoutThe AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.Get This Free Report This page (NASDAQ:KYMR) was last updated on 9/20/2026 by MarketBeat.com Staff. From Our Partners$40,000,000,000,000The national debt just hit 40 trillion dollars, and the U.S. now spends more on interest payments than on its ...American Alternative | SponsoredTrump goes "all-in" on Grand Canyon energy breakthroughA drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of...Behind the Markets | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Mid-Term Meltdown”In 2016, major election models gave Hillary Clinton a 99% chance of winning - but former CIA and Pentagon advi...Paradigm Press | SponsoredIran War: Why Is Trump Protecting THEM?A powerful Middle Eastern government is reportedly seeking US intelligence, targeting help, and military prote...Banyan Hill Publishing | SponsoredA “bloodbath” Is ComingReports suggest some Silicon Valley billionaires are stockpiling gold, guns, and gas masks - or leaving the co...TradeSmith | SponsoredBank of America: 'Digital Dollar Inevitable'Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...Decentralized Masters | SponsoredThe trade I’ve been waiting for since 2011Ross Givens, Director of Research at Traders Agency, is calling for gold to reach $10,000 an ounce this superc...Traders Agency | SponsoredWhy I went to Mount RushmoreA small miner just hit on gold in the hills surrounding Mount Rushmore, thanks to a breakthrough new technolog...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kymera Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Kymera Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
